DUSA Pharma Says Positive Results in Phase 2 Actinic

DUSA Pharmaceuticals, Inc.^® (Nasdaq: DUSA), a dermatology company that is developing and marketing its Levulan^® (aminolevulinic acid HCl) Photodynamic Therapy (PDT) platform, today announced results of an investigational study designed to examine and compare the safety and efficacy of broad area application of the Levulan^® Kerastick^® with or without occlusive dressing (where the treatment area is covered or wrapped) in conjunction with the BLU-U^® for the treatment of minimally to moderately thick actinic keratoses (AKs) on the upper extremities. The study showed a statistically significant lesion reduction and complete clearance of actinic keratoses of the extremities (hands and arms) when compared to treatment with vehicle.  The use of occlusion resulted in a statistically significant improvement in lesion clearance rates compared to treatment without occlusion. The study utilized the Levulan^® Kerastick^® (aminolevulinic acid HCl) for Topical Solution, 20% with the BLU-U^® Blue Light Photodynamic Therapy Illuminator which is FDA approved for the treatment of minimally to moderately thick actinic keratoses (AKs) of the face or scalp.